Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female miceResearch in context

• Published in: EBioMedicine Vol. 105; p. 105185
• Main Authors: Stefan Slamanig, Irene González-Domínguez, Lauren A. Chang, Nicholas Lemus, Tsoi Ying Lai, Jose Luis Martínez, Gagandeep Singh, Victoria Dolange, Adam Abdeljawad, Shreyas Kowdle, Moataz Noureddine, Prajakta Warang, Benhur Lee, Adolfo García-Sastre, Florian Krammer, Michael Schotsaert, Peter Palese, Weina Sun
• Format: Journal Article
• Language: English
• Published: Elsevier 01.07.2024
• Subjects: COVID-19; Low cost vaccine platform; mRNA vaccine; Mucosal immune response; NDV vector; Variant vaccine
• ISSN: 2352-3964

Background: In order to prevent the emergence and spread of future variants of concern of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developing vaccines capable of stopping transmission is crucial. The SARS-CoV-2 vaccine NDV-HXP-S can be administered live intranasally (IN) and thus induce protective immunity in the upper respiratory tract. The vaccine is based on Newcastle disease virus (NDV) expressing a stabilised SARS-CoV-2 spike protein. NDV-HXP-S can be produced as influenza virus vaccine at low cost in embryonated chicken eggs. Methods: The NDV-HXP-S vaccine was genetically engineered to match the Omicron variants of concern (VOC) BA.1 and BA.5 and tested as an IN two or three dose vaccination regimen in female mice. Furthermore, female mice intramuscularly (IM) vaccinated with mRNA-lipid nanoparticles (LNPs) were IN boosted with NDV-HXP-S. Systemic humoral immunity, memory T cell responses in the lungs and spleens as well as immunoglobulin A (IgA) responses in distinct mucosal tissues were characterised. Findings: NDV-HXP-S Omicron variant vaccines elicited high mucosal IgA and serum IgG titers against respective SARS-CoV-2 VOC in female mice following IN administration and protected against challenge from matched variants. Additionally, antigen-specific memory B cells and local T cell responses in the lungs were induced. Host immunity against the NDV vector did not interfere with boosting. Intramuscular vaccination with mRNA-LNPs was enhanced by IN NDV-HXP-S boosting resulting in improvement of serum neutralization titers and induction of mucosal immunity. Interpretation: We demonstrate that NDV-HXP-S Omicron variant vaccines utilised for primary immunizations or boosting efficiently elicit humoral and cellular immunity. The described induction of systemic and mucosal immunity has the potential to reduce infection and transmission. Funding: This work was partially funded by the NIAID Centers of Excellence for Influenza Research and Response (CEIRR) and by the NIAID Collaborative Vaccine Innovation Centers and by institutional funding from the Icahn School of Medicine at Mount Sinai. See under Acknowledgements for details.